1. Home
  2. NHS vs GNFT Comparison

NHS vs GNFT Comparison

Compare NHS & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NHS
  • GNFT
  • Stock Information
  • Founded
  • NHS 2003
  • GNFT 1999
  • Country
  • NHS United States
  • GNFT France
  • Employees
  • NHS N/A
  • GNFT N/A
  • Industry
  • NHS Trusts Except Educational Religious and Charitable
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NHS Finance
  • GNFT Health Care
  • Exchange
  • NHS Nasdaq
  • GNFT Nasdaq
  • Market Cap
  • NHS 232.6M
  • GNFT 186.3M
  • IPO Year
  • NHS N/A
  • GNFT 2019
  • Fundamental
  • Price
  • NHS $7.41
  • GNFT $3.79
  • Analyst Decision
  • NHS
  • GNFT Strong Buy
  • Analyst Count
  • NHS 0
  • GNFT 1
  • Target Price
  • NHS N/A
  • GNFT $13.00
  • AVG Volume (30 Days)
  • NHS 111.8K
  • GNFT 3.6K
  • Earning Date
  • NHS 01-01-0001
  • GNFT 04-24-2025
  • Dividend Yield
  • NHS 13.44%
  • GNFT N/A
  • EPS Growth
  • NHS N/A
  • GNFT N/A
  • EPS
  • NHS N/A
  • GNFT 0.03
  • Revenue
  • NHS N/A
  • GNFT $73,187,701.00
  • Revenue This Year
  • NHS N/A
  • GNFT $15.98
  • Revenue Next Year
  • NHS N/A
  • GNFT N/A
  • P/E Ratio
  • NHS N/A
  • GNFT $121.41
  • Revenue Growth
  • NHS N/A
  • GNFT 105.01
  • 52 Week Low
  • NHS $6.95
  • GNFT $2.55
  • 52 Week High
  • NHS $9.17
  • GNFT $6.42
  • Technical
  • Relative Strength Index (RSI)
  • NHS 39.77
  • GNFT 52.34
  • Support Level
  • NHS $7.53
  • GNFT $3.44
  • Resistance Level
  • NHS $7.61
  • GNFT $3.81
  • Average True Range (ATR)
  • NHS 0.06
  • GNFT 0.18
  • MACD
  • NHS -0.01
  • GNFT 0.02
  • Stochastic Oscillator
  • NHS 13.45
  • GNFT 94.55

About NHS Neuberger Berman High Yield Strategies Fund

Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Share on Social Networks: